Gluten Free Diet in IBS Patients Stratified According to Their Antigliadin Status

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2016-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gluten-free diet has been shown to improve gut symptoms in patients with celiac disease and also in adult patients with diagnosis of Irritable Bowel Syndrome (Rome III criteria).

Antibodies to native gliadin (AGA) have been suggested as a potential diagnostic marker of response to GFD. However, this has not been tested in a prospective study in IBS patients. Identification of predictors of a symptomatic response to GFD within the IBS population would improve the clinical management of these patients.

The purpose of this study is to evaluate the effect of gluten-free diet on gastrointestinal symptoms and gut motility in patients with Irritable Bowel Syndrome stratified according to their antigliadin antibodies status.

Additional purposes include investigating effects gluten free diet may have on other parameters:

* Improvement of mood
* Quality of life and general well-being
* Changes in gut microbiota

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders

NCT04872439

Autoimmune Gastrointestinal Dysmotility

ACTIVE_NOT_RECRUITING

INF-α Innate Immune Response to Gliadin

NCT03221647

Celiac Disease

COMPLETED

Gluten-free Diet in Gluten-genetically Predisposed Subjects

NCT00677495

Genetic Predisposition to Disease Celiac Disease

COMPLETED NA

Detection of Immunotoxic Gluten Peptides in Feces

NCT01478867

Celiac Disease

COMPLETED

Influence of the Immunosystem in Non-celiac Glutensensitivity

NCT03268720

Gluten Sensitivity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IBS - Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Intervention GFD in IBS and HV(controls)

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gluten free diet

Single arm

Group Type EXPERIMENTAL

Gluten free diet

Intervention Type OTHER

Gluten-free diet- Instructions provided by a dietitian

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gluten free diet

Gluten-free diet- Instructions provided by a dietitian

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients
* IBS diagnosis (Rome III)
* Willingness to participate

Exclusion Criteria

* history of any organic disease including celiac disease
* Immune deficiency
* Major abdominal surgery
* Use of immunosuppressants, glucocorticosteroids or opioids
* Use of antibiotics in the last 3 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes